{"cluster": 36, "subcluster": 13, "abstract_summ": "As expected, studies highlighted the great susceptibility of cancer patients to COVID-19 and more severe complications, leading oncologists to deeply rethink patient cancer care.Also, we focused on several molecular insights that could explain why IBD patients appear to not have higher risks of infection and worse outcome in COVID-19 than the general population, in attempt to provide scientific support for safer decisions in IBD patient care.As cancer patients are clinically known to be predisposed to COVID-19 infection, a corollary question of whether COVID-19 infection predisposes to cancer is explored.Finally additional and concrete recommendations are provided, supporting oncologists and pharmacists in their efforts to manage cancer patients and to optimize their treatments in this new era related to COVID-19.The novel coronavirus respiratory illness (COVID-19) is a public health emergency of global concern.Mortality rates from COVID-19 according to melanoma treatment type were 16%, 15% and 36% for patients on immunotherapy, targeted drugs, and for those that were not undergoing active cancer treatment, respectively.", "title_summ": "COVID-19 and Inflammatory Bowel Diseases: risk assessment, shared molecular pathways and therapeutic challengesCancer immunotherapy does not increase the risk of death by COVID-19 in melanoma patientsUnderstanding novel COVID-19: its impact on organ failure and risk assessment for diabetic and cancer patientsDeveloping a risk assessment score for cancer patients during COVID-19 pandemicCancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safetyCoronavirus infection and immune system: an insight of COVID-19 in cancer patientsClinical sequelae of the novel coronavirus: does COVID-19 infection predispose patients to cancer?Treating Leukemia in the Time of COVID-19Clinical course of COVID-19 infection in elderly patient with melanoma on nivolumab.", "title_abstract_phrases": "As expected, studies highlighted the great susceptibility of cancer patients to COVID-19 and more severe complications, leading oncologists to deeply rethink patient cancer care.Finally additional and concrete recommendations are provided, supporting oncologists and pharmacists in their efforts to manage cancer patients and to optimize their treatments in this new era related to COVID-19.Coronavirus infection and immune system: an insight of COVID-19 in cancer patientsThe novel coronavirus respiratory illness (COVID-19) is a public health emergency of global concern.Also, we focused on several molecular insights that could explain why IBD patients appear to not have higher risks of infection and worse outcome in COVID-19 than the general population, in attempt to provide scientific support for safer decisions in IBD patient care.Cancer immunotherapy does not increase the risk of death by COVID-19 in melanoma patientsBackground: Covid-19 pandemic by the new coronavirus SARS-Cov-2 has produced devastating effects on the health care system, affecting also cancer patient care.Mortality rates from COVID-19 according to melanoma treatment type were 16%, 15% and 36% for patients on immunotherapy, targeted drugs, and for those that were not undergoing active cancer treatment, respectively."}